Melola Discovery

← Melola Discovery

Akses terbuka Jurnal SINTA 1

Effectivity of Erythropoietin Alpha Compared to Erythropoietin Beta in Patients with Chronic Kidney Disease-Anemia on Hemodialysis

Folia Medica Indonesiana · Vol. 55 No. 2 (2019) · hlm. 82–82

DOI
10.20473/fmi.v55i2.24461
ISSN
2355-8393, 2599-056X
Terbit
2019-07-12
Penerbit
Airlangga University
Bahasa
en
Lisensi
creativecommons.org/licenses/by-nc-sa/4.0/

Abstrak

Anemia in patient with chronic kidney disease could cause a lot of complication. The first line therapy of this condition is by treating with erythropoiesis-stimulating agents (ESA) or called erythropoietin. The erythropoietin alpha and beta were two types of the human recombinant erythropoietin that are usually used in Indonesia. The aim of this study was to determine the effectivity of erythropoietin alpha compared to erythropoietin beta especially in haemoglobin and haematocrit level. This prospective observational study was conducted in March – September 2016. The inclusion criteria were CKD stage 5 patients with a minimum of 3 months of regular hemodialysis, Hb 20% and FS > 200ng/mL. The methology of this study had been approved by the Health Research Ethics Committee of the Bhayangkara H.S. Samsoeri Mertojoso Hospital, Surabaya. Patients received 2000 IU subcutaneous erythropoietin twice a week on both groups. Blood sample was withdrawn in pre-treatment and after 4 weeks of post erythropoietin therapy treatment for measurement of haemoglobin and haematocrit. Target for this erythropoietin therapy are increase of Hb 0.5 – 1.5 g/dL (not to exceed 12 g/dL) and increase of Hct level 2 – 4 % in 4 weeks. Based on the inclusion criteria, there were 20 patients in this study (10 patient each of both erythropoietin alpha either beta group) that consist of 7 women and 13 men. After the treatment, the mean of increased haemoglobin level for erythropoietin alpha group was 1.28 ± 0.80 g/dL (p=0.001) and erythropoietin beta was 0.37 ± 0.95 g/dL (p=0.254). The mean of increased haematocrit level for erytropoietin alpha group was 3.56 ± 3.46 % (p=0.010) and erythropoietin beta was 1.34 ± 2.71 % (p=0.152). In comparison of haemoglobin and haematocrit achievement in both groups showed that erythropoietin alpha gave better achievement in haemoglobin parameter (p=0.033), but there were no differences in both groups on haematocrit parameters (p=0.127).

Kata kunci

Jaringan kolaborasi para penulis

25 penulis · 59 tautan kepenulisan bersama · 8 lintas organisasi

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Universitas Airlangga
  • State University of Makassar
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Mahardian RahmadiUniversitas Airlangga2
Junaidi KhotibUniversitas Airlangga2
Eddy RahardjoUniversitas Airlangga2
Dewi Wara ShintaUniversitas Airlangga2
Andi Bulqiah NurState University of Makassar1
Moch YusufUniversitas Airlangga1
YulistianiUniversitas Airlangga1
Wulida Nuril FajriyahState University of Makassar1
Zam Zami JauhariUniversitas Airlangga1
Diyah WahyuniUniversitas Airlangga1
Ramadi Satryo WicaksonoAfiliasi tidak diketahui1
Abdul Kadir JaelaniAfiliasi tidak diketahui1
Vini Siane TanaemUniversitas Airlangga1
Yulistiani YulistianiUniversitas Airlangga1
Mida PurwiningtyasUniversitas Airlangga1
Bayu Dharma SantiAfiliasi tidak diketahui1
Sarah Puspita AtmajaUniversitas Airlangga1
Dwi Hari SusiloUniversitas Airlangga1
Ria Fitrah ArfianiUniversitas Airlangga1
Agung Dwi Wahyu WidodoUniversitas Airlangga1
Muhammad Thariq NadhafiAfiliasi tidak diketahui1
Bambang WahjuprajitnoAfiliasi tidak diketahui1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OpenAlex API (jurnal SINTA, ADR 0048) https://openalex.org/S4210179714, pertama di-harvest 19 Nov 2026, terakhir terlihat 19 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"><dc:title xml:lang="en">Effectivity of Erythropoietin Alpha Compared to Erythropoietin Beta in Patients with Chronic Kidney Disease-Anemia on Hemodialysis</dc:title><dc:creator>Anak Agung Ngurah Putra Riana Prasetya</dc:creator><dc:creator>Budi Suprapti</dc:creator><dc:creator>Bayu Dharma Shanti</dc:creator><dc:subject>anemia of chronic kidney disease</dc:subject><dc:subject>hemodialysis</dc:subject><dc:subject>erythropoiesis-stimulating agents</dc:subject><dc:subject>hemoglobin response</dc:subject><dc:subject>recombinant human erythropoietin</dc:subject><dc:subject>end-stage renal disease</dc:subject><dc:subject>iron status</dc:subject><dc:subject>subcutaneous administration</dc:subject><dc:subject>treatment efficacy comparison</dc:subject><dc:subject>iron deficiency anemia</dc:subject><dc:description xml:lang="en">Anemia in patient with chronic kidney disease could cause a lot of complication. The first line therapy of this condition is by treating with erythropoiesis-stimulating agents (ESA) or called erythropoietin. The erythropoietin alpha and beta were two types of the human recombinant erythropoietin that are usually used in Indonesia. The aim of this study was to determine the effectivity of erythropoietin alpha compared to erythropoietin beta especially in haemoglobin and haematocrit level. This prospective observational study was conducted in March – September 2016. The inclusion criteria were CKD stage 5 patients with a minimum of 3 months of regular hemodialysis, Hb &lt;10 g/dL with enough iron status ST &gt; 20% and FS &gt; 200ng/mL. The methology of this study had been approved by the Health Research Ethics Committee of the Bhayangkara H.S. Samsoeri Mertojoso Hospital, Surabaya. Patients received 2000 IU subcutaneous erythropoietin twice a week on both groups. Blood sample was withdrawn in pre-treatment and after 4 weeks of post erythropoietin therapy treatment for measurement of haemoglobin and haematocrit. Target for this erythropoietin therapy are increase of Hb 0.5 – 1.5 g/dL (not to exceed 12 g/dL) and increase of Hct level 2 – 4 % in 4 weeks. Based on the inclusion criteria, there were 20 patients in this study (10 patient each of both erythropoietin alpha either beta group) that consist of 7 women and 13 men. After the treatment, the mean of increased haemoglobin level for erythropoietin alpha group was 1.28 ± 0.80 g/dL (p=0.001) and erythropoietin beta was 0.37 ± 0.95 g/dL (p=0.254). The mean of increased haematocrit level for erytropoietin alpha group was 3.56 ± 3.46 % (p=0.010) and erythropoietin beta was 1.34 ± 2.71 % (p=0.152). In comparison of haemoglobin and haematocrit achievement in both groups showed that erythropoietin alpha gave better achievement in haemoglobin parameter (p=0.033), but there were no differences in both groups on haematocrit parameters (p=0.127).</dc:description><dc:publisher>Airlangga University</dc:publisher><dc:date>2019-07-12</dc:date><dc:type>info:eu-repo/semantics/article</dc:type><dc:format>application/pdf</dc:format><dc:identifier>https://doi.org/10.20473/fmi.v55i2.24461</dc:identifier><dc:identifier>10.20473/fmi.v55i2.24461</dc:identifier><dc:source>Folia Medica Indonesiana; Vol 55 No 2 (2019); 82-82</dc:source><dc:source>2355-8393</dc:source><dc:source>2599-056X</dc:source><dc:language>en</dc:language><dc:relation>https://e-journal.unair.ac.id/FMI/article/download/24461/13270</dc:relation><dc:rights>https://creativecommons.org/licenses/by-nc-sa/4.0/</dc:rights></oai_dc:dc>